Paris-based Generare, a biotech company, announced on Tuesday that it has secured €5M in Seed funding from Teampact.ventures, Galion.Exe, and EU-backed VIVES Partners.
Synbioven, Saras Capital, and Better Angle also participated among a host of renowned business angels.
The French company will use the funds to refine its technology, expand its library of genetic data, and further industrialise its approach.
Guillaume Vandenesch, CEO, Generare.bio, says, “At Generare, we are unlocking nature’s untapped potential, translating the complexity of microbial DNA into a scalable platform that can transform drug discovery. By leveraging cutting-edge biotechnology and data, we are accelerating the identification of new bioactive molecules, for medicine and beyond.”
Generare: Discovering new medicines & molecules hiding in microbes
Founded in 2023 by serial entrepreneurs and operators Guillaume Vandenesch and Dr Vincent Libis, Generare provides a data-driven discovery platform built on a decade of research into synthetic biology, DNA sequencing, and computational biology.
It takes bacteria found in soil and breaks down their genetic code to uncover untapped bioactive molecules, called Natural Products (NPs).
The company is using shotgun cloning to break thousands of genomes into millions of random fragments.
Each fragment can be cloned and analysed in parallel to identify molecules with bioactive properties like antibiotics or anticancer effects.
This method is faster and more cost-effective than targeting specific gene clusters or synthesising compounds one at a time.
According to the company, it also creates a virtuous circle of discovery because when Generare gathers more data, it has a better understanding of which clusters are most likely to yield valuable molecules.
As a result, the team can focus on the most productive samples and expand Generare’s growing molecular “library”.
The firm recently signed a partnership with French biotech, Aurobac Therapeutics, to accelerate the discovery and development of novel drugs.
The company is also hiring for its engineering and lab teams internationally.
What do the investors have to say?
Teampact Ventures is dedicated to investing in mission-driven startups poised to make a positive impact.
Romain Vidal at Teampact.ventures says, “Generare’s cohesive, mission-driven team embodies our philosophy that teamwork wins championships. Its blend of scientific excellence, innovative thinking, and collaborative leadership positions the team to revolutionise natural product discovery. We are confident that the Generare team will bring about a positive shift in how new medicines are developed harnessing nature’s ingenuity.”
Galion.Exe backs entrepreneurs building software companies around enterprise, infrastructure, fintech, health & climate, with €500-€2.5M checks in €1-to-€10M rounds at the Seed stage.
Willy Braun at Galion.Exe says, “Generare is unlocking a vast reservoir of diverse, high-value bacterial molecules offering tremendous breakthrough potential in medicine, cosmetics, and agriculture. By harnessing shotgun cloning to capture complete DNA from multiple genomes at once, their platform eliminates the high costs of DNA synthesis and prevents the redundant rediscovery of already-known compounds, making it a true game changer in the industry”
01
These are the top UK-based PR agencies for startups and scale-ups in 2025